Roivant Sciences Ltd.
ROIV
37.92 $
1 day: +2.26% (+0.83 $)
The alert is saved directly without jumping back to the homepage.
Price alerts for ROIV
Please log in to view and save price alerts.
Finanzen
Company info
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Aktuelle News
-
Is Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story?
Vorschau anzeigen
Roivant Sciences reported past first-quarter 2026 results, with sales of US$1.44 million versus US$2.17 million a year earlier and a narrower net loss of US$189.84 million, reducing basic loss per share from US$0.33 to US$0.26. The combination of lower revenue yet improved loss per share highlights Roivant’s ongoing effort to manage costs while progressing its inflammation and immunology portfolio. We’ll now examine how this combination of reduced sales and a smaller quarterly net loss could...
-
Is Roivant Sciences (ROIV) Overvalued On First Quarter Results?
Vorschau anzeigen
Why Roivant Sciences Stock Is In Focus After First Quarter Results Roivant Sciences (NasdaqGS:ROIV) is in focus after reporting first quarter results for the period ended June 30, 2026. Sales were US$1.44 million, while the company reported a net loss of US$189.84 million. The loss from continuing operations translated into a basic loss per share of US$0.26. Investors are now weighing how these figures, together with the updated loss profile, fit into the broader story for this clinical stage...
-
Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ...
Vorschau anzeigen
Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.
-
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Vorschau anzeigen
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
-
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Vorschau anzeigen
BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to report its financial results for the first quarter ended June 30, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentati